Does one model fit all? Predicting non-relapse mortality after allogeneic hematopoietic cell transplantation
Bone Marrow Transplant
.
2021 Jul;56(7):1720-1722.
doi: 10.1038/s41409-021-01236-7.
Epub 2021 Mar 3.
Authors
Masamitsu Yanada
1
,
Naoyuki Uchida
2
,
Tatsuo Ichinohe
3
,
Takahiro Fukuda
4
,
Junya Kanda
5
,
Yoshinobu Kanda
6
7
,
Yoshiko Atsuta
8
9
,
Hideki Nakasone
7
Affiliations
1
Aichi Cancer Center, Nagoya, Japan. myanada@aichi-cc.jp.
2
Toranomon Hospital, Tokyo, Japan.
3
Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
4
National Cancer Center Hospital, Tokyo, Japan.
5
Graduate School of Medicine, Kyoto University, Kyoto, Japan.
6
Jichi Medical University, Shimotsuke, Japan.
7
Jichi Medical University Saitama Medical Center, Saitama, Japan.
8
Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
9
Nagoya University Graduate School of Medicine, Nagoya, Japan.
PMID:
33658644
DOI:
10.1038/s41409-021-01236-7
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Hematopoietic Stem Cell Transplantation*
Transplantation, Homologous
Grants and funding
2020-1-11/Aichi Cancer Research Foundation (Aichi Cancer Research for the Promotion of Science Foundation)
18ek0510023h0002/Japan Agency for Medical Research and Development (AMED)